Market Overview

Shares Of Omeros Rocket Higher As Wedbush Lifts Target, Sees Near Tripling In Stock Price

Related OMER
Omidria Receives Positive Opinion from European Medicines Agency's Committee for Medicinal Products for Human Use
UPDATE: Omeros Beats Q4 Estimates

Omeros (NASDAQ: OMER) shares spiked over the $11 technical level in morning trade Wednesday following a mid-day research note from Wedbush's Liana Moussatos. The stock is now up more than 16 percent for the session.

Moussatos boosted her fair value estimate on Omeros from $28 to $32 while reiterating an Outperform rating.

The Wedbush analyst said, "With U.S. and EU regulators formally accepting OMS302 for review, the time clock for approval begins. With a July 2013 submission and our anticipation of a 10-month U.S. review for the OMS302 NDA, we estimate a PDUFA date in May 2014."

Moussatos does not expect any delays given the recent "stellar" results from each Phase 3 trial of OMS302.

Moussatos is modeling for peak global gross sales for the product at around $500 million. She is anticipating a possible partnership and Phase 2 results for OMS824 by the end of 2013.

With Omeros shares last trading at $11.27, Moussatos new fair value estimate suggests potential upside of more than 180 percent.

Latest Ratings for OMER

Feb 2014McNicoll Lewis VlakMaintainsBuy
Apr 2013WBB SecuritiesMaintainsStrong Buy
Apr 2013MLV & Co.Initiates Coverage onBuy

View More Analyst Ratings for OMER
View the Latest Analyst Ratings

Posted-In: Analyst Color News Price Target Reiteration FDA Analyst Ratings Movers


Related Articles (OMER)

Around the Web, We're Loving...